WuXi Biologics and Myricx Bio have entered into a license agreement, granting Myricx exclusive access to a proprietary antibody discovered through WuXi Bio’s integrated technology platforms. Myricx, a UK biotech company, will develop the antibody into a first-in-class Antibody-Drug Conjugate (ADC) based on its N-Myristoyltransferase inhibition (NMTi) payload platform. This platform is distinguished from standard payload classes, offering a unique profile over microtubule and topoisomerase inhibitors. The intention is to advance the ADC through preclinical and clinical development for challenging-to-treat solid tumors. WuXi Bio will receive an upfront payment and stands to gain development and commercialization milestone payments, along with royalties on net sales.
Dr. Chris Chen, CEO of WuXi Biologics, highlighted the significance of the agreement, emphasizing the role of their integrated platform in fostering the development of first-in-class and best-in-class biologics drugs globally. Myricx’s CEO, Dr. Robin Carr, expressed excitement about the collaboration, considering it a strategic move with WuXi Bio, a top global Contract Research, Development, and Manufacturing Organization (CRDMO). Dr. Carr believes that combining WuXi Bio’s leading antibody with Myricx’s NMTi-based payload will result in an ADC with substantial clinical differentiation in solid tumors. Positive preclinical data has fueled optimism about the potential of NMTi-ADCs, citing a highly differentiated mechanism of action, exceptional efficacy, and good tolerability across various cancer targets.
WuXi Biologics offers comprehensive end-to-end and modular discovery services, utilizing industry-leading technology platforms for antibody and biologic therapeutics. Their platforms include hybridoma technology, single B cell cloning technology, phage display and yeast display technology, immune and synthetic human scFv and VHH libraries, and bispecific antibody platforms like WuXiBody™ and SDarBody™. The company’s diverse technology platforms are backed by robust research material generation and assay development capabilities. The agreement exemplifies WuXi Biologics’ commitment to advancing cutting-edge biologics and further solidifies its position as a global leader in CRDMO.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
